Hypoxia promotes nuclear translocation and transcriptional function in the oncogenic tyrosine kinase RON
- PMID: 24903148
- DOI: 10.1158/0008-5472.CAN-13-3730
Hypoxia promotes nuclear translocation and transcriptional function in the oncogenic tyrosine kinase RON
Abstract
Tumor hypoxia drives metastatic progression, drug resistance, and posttreatment relapses, but how cancer cells adapt and evolve in response to hypoxic stress is not well understood. In this study, we address this question with the discovery that the receptor tyrosine kinase RON translocates into the nucleus of hypoxic cancer cells. In response to hypoxia, nuclear RON interacts with the hypoxia-inducible factor HIF-1α in a manner that relies on RON tyrosine kinase activity, binding to the c-JUN promoter and activating it. Mechanistic investigations revealed unexpectedly that nuclear RON played a more important role in activation of the c-JUN promoter than HIF-1α, leading to increased cell proliferation, survival adaptation, in vitro migration, and tumorigenicity under hypoxic conditions. Taken together, our results pointed to a novel function for RON as a transcriptional regulator that promotes the survival of cancer cells subjected to hypoxia. These results suggest novel implications for the use of small-molecule inhibitors or monoclonal antibodies targeting the RON kinase in the prevention or treatment of advanced cancer.
©2014 American Association for Cancer Research.
Similar articles
-
RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin.Aging (Albany NY). 2019 May 13;11(9):2735-2748. doi: 10.18632/aging.101945. Aging (Albany NY). 2019. PMID: 31085796 Free PMC article.
-
RON Nuclear Translocation under Hypoxia Potentiates Chemoresistance to DNA Double-Strand Break-Inducing Anticancer Drugs.Mol Cancer Ther. 2016 Feb;15(2):276-86. doi: 10.1158/1535-7163.MCT-15-0311. Epub 2016 Jan 15. Mol Cancer Ther. 2016. PMID: 26772202
-
Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.Cancer Chemother Pharmacol. 2011 May;67(5):1073-83. doi: 10.1007/s00280-010-1408-8. Epub 2010 Jul 25. Cancer Chemother Pharmacol. 2011. PMID: 20658288
-
Nuclear translocation of RON receptor tyrosine kinase. New mechanistic and functional insights.Cytokine Growth Factor Rev. 2025 Feb;81:9-15. doi: 10.1016/j.cytogfr.2024.12.004. Epub 2025 Jan 2. Cytokine Growth Factor Rev. 2025. PMID: 39794156 Review.
-
Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers.Acta Pharmacol Sin. 2006 Jun;27(6):641-50. doi: 10.1111/j.1745-7254.2006.00361.x. Acta Pharmacol Sin. 2006. PMID: 16723080 Review.
Cited by
-
Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer.J Exp Clin Cancer Res. 2020 Jun 15;39(1):110. doi: 10.1186/s13046-020-01616-9. J Exp Clin Cancer Res. 2020. PMID: 32536347 Free PMC article. Review.
-
RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin.Aging (Albany NY). 2019 May 13;11(9):2735-2748. doi: 10.18632/aging.101945. Aging (Albany NY). 2019. PMID: 31085796 Free PMC article.
-
Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.FEBS J. 2015 Oct;282(19):3693-721. doi: 10.1111/febs.13342. Epub 2015 Jul 4. FEBS J. 2015. PMID: 26096795 Free PMC article. Review.
-
Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions.J Vis Exp. 2018 Aug 2;(138):57836. doi: 10.3791/57836. J Vis Exp. 2018. PMID: 30124647 Free PMC article.
-
An Introduction and Overview of RON Receptor Tyrosine Kinase Signaling.Genes (Basel). 2023 Feb 17;14(2):517. doi: 10.3390/genes14020517. Genes (Basel). 2023. PMID: 36833444 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous